VeraSeal Den Europæiske Union - dansk - EMA (European Medicines Agency)

veraseal

instituto grifols, s.a. - humant fibrinogen, human thrombin - hemostase, kirurgisk - antihemorrhagics - understøttende behandling hos voksne, hvor standard kirurgiske teknikker er utilstrækkelige:for forbedring af haemostasisas sutur støtte i karkirurgi.

Ebvallo Den Europæiske Union - dansk - EMA (European Medicines Agency)

ebvallo

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Hirudoid 3 mg/g salve Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

hirudoid 3 mg/g salve

stada arzneimittel ag - mucopolysaccharidpolysvovlsyreester - salve - 3 mg/g

Constella Den Europæiske Union - dansk - EMA (European Medicines Agency)

constella

abbvie deutschland gmbh & co. kg - linaclotide - irritabelt tarmsyndrom - lægemidler til forstoppelse - constella er indiceret til symptomatisk behandling af moderat til svær irritabel tarmsyndrom med forstoppelse (ibs-c) hos voksne.

Ultomiris Den Europæiske Union - dansk - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - hemoglobinuri, paroxysmal - selektive immunosuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Vibativ Den Europæiske Union - dansk - EMA (European Medicines Agency)

vibativ

theravance biopharma ireland umited - telavancin - pneumonia, bacterial; cross infection - antibakterielle midler til systemisk brug, - vibativ er indiceret til behandling af voksne med nosokomiel pneumoni herunder respirator-associeret pneumoni, kendt eller mistænkt for at være forårsaget af methicillin-resistente staphylococcus aureus (mrsa). vibativ bør kun anvendes i situationer, hvor det er kendt eller mistanke om, at andre alternativer ikke er egnet. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..

Nplate Den Europæiske Union - dansk - EMA (European Medicines Agency)

nplate

amgen europe b.v. - romiplostim - purpura, trombocytopenisk, idiopatisk - antihemorrhagics - adults:nplate is indicated for the treatment of primary immune thrombocytopenia  (itp) in adult patients who are refractory to other treatments (e. kortikosteroider, immunglobuliner). paediatrics:nplate is indicated for the treatment of chronic primary immune thrombocytopenia (itp) in paediatric patients one year of age and older who are refractory to other treatments (e. kortikosteroider, immunglobuliner).

Safari 50 WG Vanddispergerbart granulat Danmark - dansk - SEGES Landbrug & Fødevarer

safari 50 wg vanddispergerbart granulat

fmc agricultural solutions a/s (tidligere: cheminova a/s) - triflusulfuron-methyl, triflusulfuron - vanddispergerbart granulat - 500 g/kg triflusulfuron-methyl ; (~ 486 g/kg triflusulfuron)